Opendata, web and dolomites

PROSKit SIGNED

Prostate cancer urinary diagnostic kit based on RNA biomarkers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROSKit project word cloud

Explore the words cloud of the PROSKit project. It provides you a very rough idea of what is the project "PROSKit" about.

preparation    assay    validate    anywhere    surgery    unnecessary    stabilization    thousands    false    care    license    arcis    biomarker    rna    patient    diagnosis    biopsies    requiring    biotechnology    preserving    revenues    stability    tested    mix    dna    blood    reduce    10    patients    intact    cancer    85    urine    validation    platform    gt    minutes    core    competitors    biopsy    poc    pca3    laboratory    positive    14    simultaneously    nucleic    days    lab    extend    proposing    discriminative    specialized    chemicals    diagnostic    molecular    temperature    invasively    certify    clinical    location    perform    collection    holdings    respect    ready    proskit    weeks    home    protocol    tools    biomarkers    central    amplifiable    specificity    11    informative    capability    kits    accurate    rapid    hours    proprietary    60    stabilise    lt    room    2025    collect    sensitivity    segment    collected    offers    analysed    psa    throughput    inexpensive    28    device    validated    acids    billion    point    market    price    patented    business    prostate    tests    sampling    samples    environment    unstable   

Project "PROSKit" data sheet

The following table provides information about the project.

Coordinator
ARCIS BIOTECHNOLOGY HOLDINGS LIMITED 

Organization address
address: SUITE F42, THE INNOVATION CENTRE KECKWICK LANE
city: DARESBURY WARRINGTON
postcode: WA4 4FS
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARCIS BIOTECHNOLOGY HOLDINGS LIMITED UK (DARESBURY WARRINGTON) coordinator 50˙000.00

Map

 Project objective

Arcis Biotechnology Holdings developed and patented PROSKit, a molecular diagnostic platform for the diagnosis of prostate cancer based on urine analysis, able to reduce the number of false positive from the PSA test and so the number of unnecessary biopsies. PROSKit is a proprietary mix of chemicals, that can stabilise nucleic acids (RNA/DNA) in urine for up to 2 weeks at room temperature and then allow sampling at home or Point of Care (PoC) using a patient-friendly sample collection technology, preserving unstable RNA biomarkers and analysis in specialized clinical environment through the PCA3 biomarker. With respect to current diagnostic methods (PSA biopsy), PROSKit offers i) Rapid- samples ready for analysis in <3 minutes, results in <2 hours if tested at surgery, compared to days for biopsy, ii) Accurate- greater sensitivity and specificity than current PSA blood test: PCA3 presents a 28% higher discriminative capability than PSA; iii) Inexpensive- as informative as multi-core biopsy for <10% of the price; iv) High throughput- PROSKit samples can be collected anywhere, non-invasively and thousands analysed simultaneously at a central location. Compared to competitors proposing RNA stabilization requiring laboratory analyses, complex procedures and specific tools, PROSKit offers stabilization at room temperature and with no lab equipment in 3 minutes. Intact amplifiable RNA biomarkers have already been validated for 7 days stability but needs to extend validation for >14 days, validate the protocol for patients to collect urine and analysts to perform assay; certify design of PROSKit device and cost for the device and define agreement with partners for distribution and license for execution of tests. DNA/RNA Sample preparation business market revenues are expected to reach 1.85 billion € in 2025. Kits segment represents 60% of the market: 1.11 billion € in 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROSKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROSKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More